Nuvation Bio Inc. NUVB
We take great care to ensure that the data presented and summarized in this overview for Nuvation Bio Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVB
View all-
Decheng Capital LLC Menlo Park, CA26MShares$56.6 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$35.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$34.3 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$28.5 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$20.1 Million5.46% of portfolio
-
Laurion Capital Management LP New York, NY6.49MShares$14.2 Million0.33% of portfolio
-
Geode Capital Management, LLC Boston, MA4.95MShares$10.8 Million0.0% of portfolio
-
State Street Corp Boston, MA4.6MShares$10 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.16MShares$9.08 Million1.66% of portfolio
-
Tang Capital Management LLC San Diego, CA3.9MShares$8.5 Million0.78% of portfolio
Latest Institutional Activity in NUVB
Top Purchases
Top Sells
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Insider Transactions at NUVB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 07
2025
|
David Hung PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
300,000
+0.51%
|
$300,000
$1.62 P/Share
|
|
Apr 04
2025
|
David Hung PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
200,000
+0.34%
|
$200,000
$1.66 P/Share
|
|
Apr 01
2025
|
Robert Mashal |
BUY
Open market or private purchase
|
Indirect |
100,000
+17.08%
|
$100,000
$1.67 P/Share
|
|
Nov 11
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
SELL
Open market or private sale
|
Direct |
56,361
-1.44%
|
$112,722
$2.89 P/Share
|
|
Oct 08
2024
|
Robert Mashal |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$200,000
$2.2 P/Share
|
|
Sep 04
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Conversion of derivative security
|
Indirect |
1,695,700
+43.01%
|
-
|
|
Sep 04
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Conversion of derivative security
|
Direct |
2,543,600
+39.34%
|
-
|
|
Sep 04
2024
|
Xiangmin Cui |
BUY
Conversion of derivative security
|
Indirect |
19,004,200
+42.14%
|
-
|
|
Jun 25
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
277,895
+10.18%
|
$555,790
$2.97 P/Share
|
|
Jun 24
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
336,874
+13.41%
|
$673,748
$2.98 P/Share
|
|
Jun 21
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
75,411
+3.94%
|
$226,233
$3.0 P/Share
|
|
Jun 20
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
87,715
+4.74%
|
$175,430
$2.99 P/Share
|
|
Jun 11
2024
|
Kim D Blickenstaff |
BUY
Open market or private purchase
|
Indirect |
172,189
+50.0%
|
$344,378
$2.9 P/Share
|
|
May 24
2024
|
Daniel G Welch |
BUY
Exercise of conversion of derivative security
|
Direct |
659,947
+42.86%
|
$659,947
$1.69 P/Share
|
|
Apr 09
2024
|
Xiangmin Cui |
BUY
Grant, award, or other acquisition
|
Indirect |
6,172,344
+50.0%
|
-
|
|
Apr 09
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Grant, award, or other acquisition
|
Indirect |
550,758
+50.0%
|
-
|
|
Apr 09
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Grant, award, or other acquisition
|
Direct |
1,378,989
+50.0%
|
-
|
|
Feb 21
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
53,000
+0.42%
|
$53,000
$1.36 P/Share
|
|
Feb 20
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
117,100
+0.92%
|
$117,100
$1.36 P/Share
|
|
Feb 19
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
5,143,000
+29.14%
|
$5,143,000
$1.26 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 23.2M shares |
|---|---|
| Open market or private purchase | 1.65M shares |
| Exercise of conversion of derivative security | 660K shares |
| Open market or private sale | 56.4K shares |
|---|